

# News Release

## Commercial News

---



### **Oridion Announces Significant Medical Research to be Presented at AARC Congress**

**Jerusalem/Needham – December 10, 2008 – Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that three substantial medical research project findings will be presented at the upcoming AARC (American Association for Respiratory Care) Congress in Anaheim, California. These studies confirm the clinical benefits of End-tidal CO<sub>2</sub> (EtCO<sub>2</sub>) monitoring using Oridion Microstream® capnography technology and clearly show that capnography needs to be included in a hospital's respiratory monitoring strategy.**

Proprietary EtCO<sub>2</sub> monitoring solutions from Oridion can increase patient safety and improve patient outcomes utilizing information from the patient's respiratory system. Oridion has focused on providing a technology that provides the clinician with a simple and accurate assessment of a patient's ventilatory status which can provide an early prediction of events. A short summary of the studies from ASA and AARC are discussed below.

An Israel Institute of Technology - Technion study concluded that EtCO<sub>2</sub> measurement contributes significantly to the prediction of events during pediatric and adult endoscopy procedures under general anesthesia and conscious sedation.

Two research studies, completed in cooperation between The Brigham and Women's Hospital (Boston, MA) and The University of Alabama in Birmingham, investigated the use of Oridion Microstream Technology and the Smart CapnoLine® H Plus CO<sub>2</sub> sampling line during the administration of supplemental oxygen delivered by a wide range of oxygen masks. These masks blow oxygen enriched breathing gas toward the patient's nose and mouth. Patients receiving oxygen are at risk for breathing difficulty which can be best monitored by measuring ventilation, which is measured by capnography. In these studies, the Oridion products revealed no significant difference in EtCO<sub>2</sub> or respiratory rate when the test subjects were breathing with and without the oxygen masks for all masks and oxygen concentrations tested. The researchers believe that this will aid patient monitoring in clinical practice.

The above medical research projects join four additional papers that were presented in October 2008 at the ASA (American Society of Anesthesiologists) Annual Meeting in Orlando, Florida. Among the studies released was a comprehensive research paper focused on Oridion's latest major initiative "IPI\* – Integrated Pulmonary Index" conducted by physician/scientists from Medical College of Georgia in Augusta. IPI helps caregivers manage four complicated monitoring parameters with a single, simplified number. IPI utilizes End-tidal CO<sub>2</sub>, respiration rate, heart rate and SpO<sub>2</sub> to provide an uncomplicated, inclusive assessment of a patient's ventilatory status.

Additional papers presented at ASA included a study from the Brigham & Women's Hospital in Boston showing that CO<sub>2</sub> measurement using the Oridion CapnoBloc™ is an effective and accurate sampling method during upper gastrointestinal endoscopy.

Another important study concluded that expert medical education and training can improve patient safety.

Furthermore, a study published in this month's issue of PEDIATRICS – The Official Journal of the American Academy of Pediatrics concluded that Microstream® capnography with its low flow rate made non-invasive capnography possible in the NICU. The study also showed that ETCO<sub>2</sub>, measured by Microstream® capnography has good correlation with PACO<sub>2</sub>, and is reliable in severe lung disease.

A full list of the medical publications can be found on the Oridion website [http://www.oridion.com/global/english/clinical\\_solutions/overview/research.html](http://www.oridion.com/global/english/clinical_solutions/overview/research.html)

Oridion is the global leader of innovative capnography monitoring solutions helping to improve patient safety, and its Microstream® capnography technology has become the standard of care in ventilation monitoring.

\*IPI is pending FDA 510(k) clearance

### **For further Oridion information please contact**

Gerry Feldman, President  
Walter Tabachnik, Chief Financial Officer  
Elena Gerberg, Investor Relations

e-mail: [investor@oridion.com](mailto:investor@oridion.com)

website: [www.oridion.com](http://www.oridion.com)

phone: +972 2 589 9159

address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

### **About Oridion**

Oridion Systems Ltd. ([www.oridion.com](http://www.oridion.com)) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO<sub>2</sub>) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from

competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.